PriceTargets.com logo

Evolent Health - EVH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.18
  • Forecasted Upside: 129.46%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 10 Buy Ratings
  • 1 Strong Buy Ratings
$11.41 As of 12/20/2024 06:31 PM ET
▲ +0.23 (2.06%)

This chart shows the closing price for EVH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evolent Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVH

Analyst Price Target is $26.18
▲ +129.46% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Evolent Health in the last 3 months. The average price target is $26.18, with a high forecast of $41.00 and a low forecast of $15.00. The average price target represents a 129.46% upside from the last price of $11.41.

This chart shows the closing price for EVH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in Evolent Health. This rating has held steady since July 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/3/2024BTIG ResearchLower TargetBuy$36.00 ➝ $29.00
11/22/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$45.00 ➝ $15.00
11/18/2024OppenheimerLower TargetOutperform ➝ Outperform$34.00 ➝ $28.00
11/13/2024CitigroupLower TargetBuy ➝ Buy$33.00 ➝ $21.00
11/12/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$20.00 ➝ $20.00
11/11/2024BarclaysLower TargetOverweight ➝ Overweight$39.00 ➝ $19.00
11/8/2024OppenheimerLower TargetOutperform ➝ Outperform$45.00 ➝ $34.00
11/8/2024StephensDowngradeOverweight ➝ Equal Weight$38.00 ➝ $16.00
10/29/2024CitigroupLower TargetBuy ➝ Buy$35.00 ➝ $33.00
10/11/2024KeyCorpInitiated CoverageOverweight$35.00
10/10/2024KeyCorpUpgradeStrong-Buy
10/8/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$42.00 ➝ $42.00
8/27/2024Truist FinancialReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
8/26/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$42.00 ➝ $42.00
8/19/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$36.00 ➝ $45.00
8/9/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$34.00 ➝ $31.00
8/9/2024Truist FinancialUpgradeHold ➝ Buy$28.00 ➝ $33.00
7/30/2024StephensReiterated RatingOverweight ➝ Overweight$42.00 ➝ $42.00
5/10/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$44.00 ➝ $41.00
5/10/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$38.00 ➝ $34.00
4/22/2024CitigroupInitiated CoverageBuy$40.00
3/28/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$45.00 ➝ $44.00
3/15/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$53.00 ➝ $52.00
3/1/2024OppenheimerInitiated CoverageOutperform$45.00
2/23/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$37.00 ➝ $38.00
2/23/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$47.00 ➝ $45.00
1/9/2024William BlairReiterated RatingOutperform
1/3/2024BarclaysInitiated CoverageOverweight$39.00
12/6/2023JMP SecuritiesInitiated CoverageOutperform$37.00
11/28/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$44.00 ➝ $42.00
11/16/2023WedbushReiterated RatingOutperform
11/14/2023Truist FinancialLower TargetHold ➝ Hold$36.00 ➝ $34.00
10/16/2023UBS GroupInitiated CoverageBuy$46.00
8/14/2023GuggenheimReiterated RatingBuy ➝ Buy$47.00
6/26/2023GuggenheimLower Target$50.00 ➝ $47.00
4/11/2023StephensInitiated CoverageOverweight$40.00
2/23/2023BTIG ResearchBoost Target$40.00 ➝ $45.00
2/23/2023Royal Bank of CanadaReiterated RatingOutperform$44.00
1/30/2023CowenBoost TargetOutperform$57.00 ➝ $59.00
1/6/2023Piper SandlerBoost Target$44.00 ➝ $51.00
12/5/2022Piper SandlerBoost Target$33.00 ➝ $44.00
11/18/2022CowenBoost TargetOutperform$52.00 ➝ $57.00
11/18/2022CowenBoost TargetOutperform$52.00 ➝ $57.00
11/17/2022Truist FinancialLower Target$32.00
11/4/2022Piper SandlerLower TargetOverweight$40.00 ➝ $33.00
11/3/2022Canaccord Genuity GroupLower Target$48.00 ➝ $44.00
11/1/2022Truist FinancialInitiated CoverageHold$33.00
10/12/2022Canaccord Genuity GroupLower Target$55.00 ➝ $48.00
10/12/2022BTIG ResearchLower TargetBuy$55.00 ➝ $45.00
8/25/2022BTIG ResearchBoost Target$50.00 ➝ $55.00
8/19/2022JPMorgan Chase & Co.Boost TargetOverweight$37.00 ➝ $52.00
8/15/2022GuggenheimBoost Target$45.00
8/4/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$45.00 ➝ $55.00
8/3/2022Piper SandlerBoost TargetOverweight$35.00 ➝ $40.00
8/3/2022BTIG ResearchBoost TargetBuy$45.00 ➝ $50.00
8/3/2022Royal Bank of CanadaBoost TargetOutperform$40.00 ➝ $44.00
7/29/2022Royal Bank of CanadaReiterated RatingInitiates
7/28/2022Royal Bank of CanadaInitiated CoverageOutperform$40.00
7/25/2022CowenBoost Target$52.00
6/21/2022CowenBoost TargetOutperform$48.00 ➝ $50.00
6/21/2022CowenBoost TargetOutperform$48.00 ➝ $50.00
5/17/2022Piper SandlerLower TargetNA$37.00 ➝ $35.00
5/9/2022Canaccord Genuity GroupBoost Target$40.00 ➝ $45.00
3/29/2022GuggenheimInitiated CoverageBuy$43.00
3/25/2022BTIG ResearchBoost TargetBuy$35.00 ➝ $40.00
2/24/2022Piper SandlerLower Target$36.00 ➝ $32.00
11/18/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$26.00 ➝ $37.00
11/4/2021Piper SandlerBoost TargetOverweight$30.00 ➝ $36.00
9/13/2021BTIG ResearchBoost TargetBuy$30.00 ➝ $35.00
8/5/2021Piper SandlerBoost TargetOverweight$29.00 ➝ $30.00
5/6/2021Piper SandlerBoost TargetOverweight$27.00 ➝ $29.00
4/29/2021JPMorgan Chase & Co.Initiated CoverageNeutral
2/26/2021CowenBoost TargetOutperform$19.00 ➝ $25.00
2/26/2021BTIG ResearchBoost TargetBuy$20.00 ➝ $25.00
2/26/2021Piper SandlerBoost TargetOverweight$25.00 ➝ $27.00
1/19/2021Piper SandlerReiterated RatingPositive ➝ Overweight$15.00 ➝ $25.00
1/6/2021BTIG ResearchInitiated CoverageBuy$20.00
11/6/2020Piper SandlerLower TargetOverweight$16.00 ➝ $15.00
10/8/2020Piper SandlerLower TargetOverweight$17.00 ➝ $16.00
8/5/2020Truist FinancialBoost TargetBuy$15.00 ➝ $20.00
8/5/2020Cantor FitzgeraldBoost TargetPositive ➝ Neutral$10.00 ➝ $13.00
7/20/2020Robert W. BairdBoost TargetOutperform$10.00 ➝ $12.00
7/20/2020SunTrust BanksBoost TargetBuy$14.00 ➝ $15.00
6/26/2020JPMorgan Chase & Co.Boost TargetNeutral$8.00 ➝ $11.00
6/5/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$13.00 ➝ $8.00
6/2/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$9.00 ➝ $8.00
6/1/2020Cantor FitzgeraldLower TargetOverweight ➝ Overweight$14.00 ➝ $9.00
5/8/2020SunTrust BanksBoost TargetBuy$12.00 ➝ $14.00
3/26/2020SunTrust BanksLower TargetBuy$16.00 ➝ $12.00
2/26/2020Piper SandlerBoost TargetOverweight$10.15 ➝ $17.00
2/26/2020Cantor FitzgeraldReiterated RatingOverweight$16.00 ➝ $14.00
1/23/2020Cantor FitzgeraldBoost TargetOverweight$10.00 ➝ $16.00
1/8/2020Wells Fargo & CompanyLower TargetOverweight$19.00 ➝ $17.00
12/30/2019Cantor FitzgeraldReiterated RatingBuy$10.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.22 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 10 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 7 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 12 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 13 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 16 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 9 very positive mentions
  • 20 positive mentions
  • 10 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 18 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 18 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Evolent Health logo
Evolent Health, Inc., through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Read More

Today's Range

Now: $11.41
Low: $10.96
High: $11.52

50 Day Range

MA: $16.97
Low: $10.71
High: $27.14

52 Week Range

Now: $11.41
Low: $10.53
High: $35.00

Volume

3,134,905 shs

Average Volume

1,868,250 shs

Market Capitalization

$1.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Evolent Health?

The following Wall Street research analysts have issued research reports on Evolent Health in the last twelve months: Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., JMP Securities, JPMorgan Chase & Co., KeyCorp, Oppenheimer Holdings Inc., Royal Bank of Canada, Stephens, Truist Financial Co., and William Blair.
View the latest analyst ratings for EVH.

What is the current price target for Evolent Health?

0 Wall Street analysts have set twelve-month price targets for Evolent Health in the last year. Their average twelve-month price target is $26.18, suggesting a possible upside of 129.5%. Canaccord Genuity Group Inc. has the highest price target set, predicting EVH will reach $41.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $15.00 for Evolent Health in the next year.
View the latest price targets for EVH.

What is the current consensus analyst rating for Evolent Health?

Evolent Health currently has 1 hold rating, 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EVH will outperform the market and that investors should add to their positions of Evolent Health.
View the latest ratings for EVH.

What other companies compete with Evolent Health?

Other companies that are similar to Evolent Health include Nuvei, TriNet Group, CarGurus, DXC Technology and Alight. Learn More about companies similar to Evolent Health.

How do I contact Evolent Health's investor relations team?

Evolent Health's physical mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company's listed phone number is (571) 389-6000 and its investor relations email address is [email protected]. The official website for Evolent Health is www.evolenthealth.com. Learn More about contacing Evolent Health investor relations.